Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity

Table 3 Histopathological lesion scores

Group	Mucosal necrosis	Mucosal inflammatory cells infiltration	Edema in the submucosa	Submucosal inflammatory cells infiltration	Apoptosis
Normal	0 (0–0)	0 (0–0)	0 (0–0.5)	0 (0–0)	0 (0–0)
L. acidophilus	0 (0–0)	0 (0–0.5)	0 (0–0.5)	0 (0–0)	0 (0–0)
L. plantarum	0 (0–0)	0 (0–0)	0 (0–0.5)	0 (0–0)	0 (0–0.5)
L. rhamnosus	0 (0–0)	0 (0–0)	0 (0–0.5)	0 (0–0)	0 (0–0.5)
Mixtures	0 (0–0)	0 (0–0)	0 (0–0.5)	0 (0–0)	0 (0–0.5)
Irinotecan	2 (2–3)^*	2 (2–3)^*	3 (3–3)^*	3 (2–3)^*	3 (2–3)^*
Irino + L. acidophilus	0 (0–1)	1 (0.5–1)	1 (1–1.5)	1 (0–1)	1 (1–2)
Irino + L. plantarum	0 (0–0)^a	0 (0–1)	1 (0–1)	0 (0–1)	1 (0–1)
Irino + L. rhamnosus	1 (0–1)	1 (1–2)	1 (1–1.5)	1 (1–1)	2 (1–2)
Irino + Lb. Mixtures	0 (0–0)^a	0 (0–0)^a	0 (0–0.5)^a	0 (0–0)^a	0 (0–0.5)^a

Each value represents the median and interquartile range (p25-p75) (n = 5). Statistics were carried out by the Kruskal Wallis test, followed by the Dunn test
^*Significant difference from the control group at p < 0.05
^aSignificant difference from the Irinotecan group at p < 0.05

ISSN: 1471-2180